On October 4, 2023 Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, reported that it will present preclinical data from its lead candidate, NST-628, a mechanistically novel non-degrading molecular glue that targets multiple nodes in the RAS/MAPK pathway, at the upcoming 2023 AACR (Free AACR Whitepaper)-NCI-EORTC International Conference taking place in Boston, Massachusetts from October 11 – 15, 2023 (Press release, Nested Therapeutics, OCT 4, 2023, View Source [SID1234635662]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nested Therapeutics will be presenting three posters that validate the mechanism of action and demonstrate potential superiority of NST-628 compared to other MAPK-targeted compounds. Details for the accepted abstracts are listed below.
Title: NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancers
Session Date and Time: Thursday, October 12, 12:30 – 4 pm, Level 2, Exhibit Hall D, Hynes Convention Center
Abstract Number: A086
Session: Poster Session A
Title: NST-628 is a potent, best-in-class MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers
Session Date and Time: Thursday, October 12, 12:30 – 4 pm, Level 2, Exhibit Hall D, Hynes Convention Center
Abstract Number: A088
Session: Poster Session A
Title: NST-628 is a potent, fully brain-penetrant, RAS/MAPK pathway molecular glue inhibitor with efficacy in CNS tumor models
Session Date and Time: Thursday, October 12, 12:30 – 4 pm, Level 2, Exhibit Hall D, Hynes Convention Center
Abstract Number: A089
Session: Poster Session A
About DeCRYPTion Platform
Nested Therapeutics’ DeCRYPTion Platform is a purpose-built, insightful drug discovery platform that enables Nested to identify new, overlooked areas of opportunity in the form of high value targets and design therapeutics for a perfect fit. The platform includes three critical components: (1) mapping mutational clusters onto the structural proteome, (2) identifying druggable pockets and cancer-driving mechanisms, and (3) designing novel drugs optimized for the druggable pocket.